Aurigene

Curis, Aurigene collaborate for immuno-oncology and precision oncology targets

Thursday, January 22, 2015

Curis, a Lexington, Mass.-based biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, and Aurigene Discovery Technologies, a Bangalore, India-based, specialized, discovery stage biotechnology company developing novel therapies to treat cancer and inflammatory diseases, have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets.

[Read More]